Cytarabine (Ara-C)

DRUG12 trials

Sponsors

M.D. Anderson Cancer Center, Novartis Pharmaceuticals, First Affiliated Hospital of Zhejiang University, Kura Oncology, Inc., Joanna Yi

Conditions

Acute Myeloid Leukaemia (AML)Acute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Acute T Lymphpblastic Leukemia/LymphomaChronic Myelogenous LeukemiaGraft Versus Host DiseaseLangerhans Cell HistiocytosisLeukemia

Early Phase 1

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

RecruitingNCT07059975

Joanna YiAcute Myeloid Leukemia, Pediatric AML

Start: 2025-10-22End: 2031-08-31Target: 36Updated: 2025-11-04

Phase 1

Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

CompletedNCT00004263

M.D. Anderson Cancer CenterLeukemia, Myelodysplastic Syndromes

Start: 1999-12-31End: 2007-01-31Updated: 2012-07-30

Phase 2

Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia

CompletedNCT00002833

M.D. Anderson Cancer CenterGraft Versus Host Disease, Leukemia, Myelodysplastic Syndromes

Start: 1994-10-31End: 2002-04-30Updated: 2012-07-30

VHAG in Treating R/R T-ALL/LBL

RecruitingNCT06742463

First Affiliated Hospital of Zhejiang UniversityAcute T Lymphpblastic Leukemia/Lymphoma

Start: 2024-12-31End: 2028-06-30Target: 50Updated: 2024-12-19

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

Not yet recruitingNCT07060001

The Methodist Hospital Research InstituteAcute Myeloid Leukaemia (AML), Acute Myeloid Leukemia (AML)

Start: 2026-04-01End: 2029-12-01Target: 112Updated: 2026-03-06

Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

RecruitingNCT07078591

Beijing 302 HospitalAcute Myeloid Leukemia

Start: 2025-06-20End: 2031-06-30Target: 50Updated: 2025-07-28

Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH

RecruitingNCT07187193

Cancer Institute and Hospital, Chinese Academy of Medical SciencesLangerhans Cell Histiocytosis

Start: 2025-04-12End: 2027-04-13Target: 50Updated: 2025-09-22

Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial

Not yet recruitingNCT07643103

Institute of Hematology & Blood Diseases Hospital, ChinaPh- Acute Lymphoblastic Leukemia (Ph-ALL)

Start: 2026-06-12End: 2030-05-31Target: 32Updated: 2026-06-11

Phase 2 Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."

Not yet recruitingNCT07686107

Therapeutic Advances in Childhood Leukemia ConsortiumLeukemia, Myeloid, Acute

Start: 2026-08-31End: 2030-12-31Target: 24Updated: 2026-07-07

Phase 3

Combination Chemotherapy in Treating Patients With Lymphoma

CompletedNCT00002835

M.D. Anderson Cancer CenterLymphoma

Start: 1995-10-30End: 2004-02-04Updated: 2018-11-15

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

CompletedNCT00333840

Novartis PharmaceuticalsChronic Myelogenous Leukemia

Start: 2000-06-30End: 2012-03-31Updated: 2013-10-14

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

RecruitingNCT07007312

Kura Oncology, Inc.Acute Myeloid Leukemia (AML)

Start: 2025-09-26End: 2031-11-01Target: 1300Updated: 2026-06-29

Related Papers

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Blood2025-11-031 citations

Update AML: Updated disease monitoring and treatment to enhance outcomes for pediatric AML (NCT07059975)

Blood2025-11-03

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

New England Journal of Medicine2017-03-081212 citations

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.

2008-02-06474 citations